Organigram Global (OGI) Shares Outstanding (2018 - 2026)
Organigram Global (OGI) posted quarterly Shares Outstanding (Entity) of $97.7 million for Q3 2025, up 22.75% year-on-year from $79.6 million in Q3 2024, and up 8.19% on a QoQ basis from $90.3 million in Q4 2024.
Organigram Global (OGI) Shares Outstanding (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Shares Outstanding (Entity) for 8 consecutive years, with $97.7 million the latest figure, recorded in Q3 2025.
- Quarterly Shares Outstanding (Entity) rose 22.75% year-over-year to $97.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $97.7 million (up 22.75% YoY) and the FY2025 annual result came in at $97.7 million, up 22.75% from the prior year.
- Shares Outstanding (Entity) grew to $97.7 million in Q3 2025 per OGI's latest filing, from $90.3 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for OGI reached as high as $736.9 million in Q2 2021 and fell as low as $60.1 million in Q3 2021.
- A 5-year average of $186.6 million and a median of $85.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) jumped 2101.77% — and 2022, when it climbed 1.38%.
- Year by year, Shares Outstanding (Entity) stood at $306.7 million in 2021, then sank by 80.14% to $60.9 million in 2022, then slipped by 0.62% to $60.5 million in 2023, then jumped by 49.17% to $90.3 million in 2024, then rose by 8.19% to $97.7 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $97.7 million, $90.3 million, and $79.6 million for Q3 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 8.98 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.16 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 422.10 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 455,871.00 |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 100.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 497.70 Mn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn | 127.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127.67 Mn |
| Dec 31, 2025 | 127.67 Mn |
| Sep 30, 2025 | 127.67 Mn |
| Mar 31, 2025 | 95.29 Mn |
| Dec 31, 2024 | 95.29 Mn |
| Sep 30, 2024 | 95.29 Mn |
| Sep 30, 2023 | 81.29 Mn |
| Aug 31, 2022 | 77.23 Mn |
| Nov 30, 2021 | 306.70 Mn |
| Aug 31, 2021 | 64.03 Mn |
| May 31, 2021 | 736.87 Mn |
| Feb 28, 2021 | 606.98 Mn |
| Nov 30, 2020 | 50.50 Mn |
| Aug 31, 2020 | 43.17 Mn |
| May 31, 2020 | 43.84 Mn |
| Feb 29, 2020 | 1.24 Bn |
| Nov 25, 2019 | 35.23 Mn |
| Aug 31, 2019 | 35.23 Mn |
| May 31, 2019 | 37.44 Mn |
| Feb 28, 2019 | 86.25 Mn |